ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,518 GBX | +0.32% |
|
+0.69% | +17.94% |
| 09:14am | AstraZeneca's Adjuvant Lung Cancer Drug Fails to Improve Disease-free Survival in Late-stage Trial | MT |
| 08:53am | AstraZeneca's Imfinzi Gets Positive Results in Bladder Cancer Trial | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.4
USD
Average target price
174.4
USD
Spread / Average Target
+10.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.94% | 245B | |
| +52.70% | 801B | |
| +41.83% | 631B | |
| -4.86% | 359B | |
| +21.96% | 337B | |
| +11.47% | 305B | |
| +4.21% | 231B | |
| +12.73% | 219B | |
| +10.46% | 171B | |
| -1.49% | 161B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca Says Ultomiris Gets US FDA Approval to Treat Neuromyelitis Optica Spectrum Disorder
